Back I am newly diagnosed Not yet treated

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments

I want to enter information about my genetic testing (e.g, BRCA) and/or tumor testing results

I want to filter the trials based on location, phase of development, or drug name, category or target

Results

For more information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.

NCT03180307

III

Newly diagnosed stage III ovarian cancer

A Phase 3, Randomized, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer

View Drugs

Arizona, California, Florida, Maryland, Michigan, Minnesota, Missouri, Ohio, Pennsylvania

Drug(s) in Trial	Other Drug Names	Main Known Action
OTL38	fluorescent imaging ligand OTL38	Folate receptor imaging agent

NCT03602859

III

Newly diagnosed stage III/IV non-mucinous ovarian cancer (neo-adjuvant or adjuvant and maintenance)

ENGOT-0V44 The FIRST (First-line Ovarian Cancer Treatment With Niraparib Plus TSR-042) Study: A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

View Drugs

Alaska, California, Connecticut, Florida, Illinois, Louisiana, Maryland, Massachusetts, Minnesota, Montana, New Jersey, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Texas, Utah, Virginia, Washington

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Niraparib	MK4827, Zejula	PARP inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
TSR-042	anti-PD-1 monoclonal antibody TSR-042, ANB011, Dostarlimab	Blocks PD-L1/2 inhibition of T cells

NCT03737643

III

Newly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant or adjuvant and maintenance)

A Phase III Randomised, Double-Blind, Placebo-Controlled, Multicentre Study of Durvalumab in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib in Newly Diagnosed Advanced Ovarian Cancer Patients (DUO-O).

View Drugs

California, Colorado, Florida, Georgia, Illinois, Indiana, Maryland, Michigan, Missouri, Nevada, New Mexico, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Utah

Drug(s) in Trial	Other Drug Names	Main Known Action
Bevacizumab	immunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, Avastin	VEGF antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Olaparib	AZD2281, Lynparza	PARP inhibitor
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02122185

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant or adjuvant and maintenance)

A Randomized Placebo Controlled Phase II Trial of Metformin in Conjunction With Chemotherapy Followed by Metformin Maintenance Therapy in Advanced Stage Ovarian, Fallopian Tube and Primary Peritoneal Cancer

View Drugs

Alabama, California, Illinois, Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Docetaxel	Taxotere	Microtubule stabilizer/mitotic inhibitor
Metformin	Fortamet, Glucophage, Glumetza, Riomet	AMP-activated protein kinase (AMPK) activator
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02437812

Newly diagnosed stage II-IV ovarian cancer

A Phase II, Open-Label, Non-Randomized, Pilot Study of Paclitaxel, Carboplatin and Oral Metformin for Patients Newly Diagnosed With Stage II-IV Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma

View Drugs

California

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Metformin	Fortamet, Glucophage, Glumetza, Riomet	AMP-activated protein kinase (AMPK) activator
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02520154

Newly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant)

Matched Paired Pharmacodynamics and Feasibility Study of Pembrolizumab in Combination With Chemotherapy in Frontline Ovarian Cancer

View Drugs

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT02834975

Newly diagnosed stage III/IV high grade ovarian cancer (neo-adjuvant)

Phase II Single Arm Study of Combination Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Ovarian, Fallopian Tube, or Peritoneal Carcinoma Receiving Neoadjuvant Chemotherapy

View Drugs

Florida

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT02766582

Newly diagnosed stage III/IV ovarian cancer after suboptimal debulking surgery

Phase II Open Label Nonrandomized Trial of the Anti PD 1 Therapy Pembrolizumab With First Line Platinum Based Chemotherapy Followed by 12 Months Pembrolizumab Monotherapy for Patients With Stage III/IV Epithelial Ovarian Cancer

View Drugs

Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Pembrolizumab	MK3475, SCH 900475, Lambrolizumab, Keytruda	Blocks PD-L1/2 inhibition of T cells

NCT02033616

Newly diagnosed stage III/IV ovarian cancer

Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy

View Drugs

California, Colorado

Drug(s) in Trial	Other Drug Names	Main Known Action
AVOVA-1	TAA-loaded autologous dendritic cell vaccine, Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens	Anti-tumor immune response

NCT03531645

Newly diagnosed stage III/IV low grade serous ovarian cancer (neo-adjuvant)

A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma

View Drugs

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Abemaciclib	Bemaciclib, LY2853219, CDK4/6 Dual Inhibitor LY2835219, Verzenio	CDK4/6 inhibitor
Fulvestrant	Faslodex, ICI 182,780, ZD9238	ER antagonist (SERD)

NCT03206645

Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)

Phase 1B Trial With PTC-596 in High-Grade Serous Ovarian Cancer: a Targeted Approach Toward Chemoresistant Stem-Like Cancer Cells

View Drugs

Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
PTC596	polycomb ring finger oncogene inhibitor PTC596, BMI1 inhibitor PTC596	BMI1 inhibitor

NCT03206177

Newly diagnosed, persistent, or recurrent ovarian carcinosarcoma

Feasibility IB Trial of Paclitaxel/Carboplatin + Galunisertib (a Small Molecule Inhibitor of the Kinase Domain of Type 1 TGF-B Receptor) in Patients With Newly Diagnosed, Persistent or Recurrent Carcinosarcoma of the Uterus or Ovary

View Drugs

Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Galunisertib	LY2157299	TGFBR1 antagonist
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02713386

I/II

Newly diagnosed suspected stage III/IV ovarian cancer (neo-adjuvant)

A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

View Drugs

Florida, Georgia, Illinois, Indiana, Iowa, Kentucky, Louisiana, Maryland, Michigan, Minnesota, Missouri, Nebraska, New Jersey, New Mexico, New York, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Tennessee, Texas, Virginia, Washington, West Virginia, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor
Ruxolitinib	INCB18424, Jakafi, oral Janus-associated kinase inhibitor INCB18424, oral JAK inhibitor INCB18424	JAK1/2 kinase inhibitor

NCT02726997

I/II

Newly diagnosed stage III/IV high grade non-mucinous ovarian cancer (neo-adjuvant)

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

View Drugs

Texas

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Durvalumab	Anti-B7H1 Monoclonal Antibody MEDI4736, MEDI4736, Imfinzi	Blocks PD-L1 inhibition of T cells
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT03394885

I/II

Newly diagnosed stage III-IV ovarian cancer (neo-adjuvant; inc expansion)

Atezolizumab in Combination With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery for Patients With Newly-Diagnosed Advanced-Stage Epithelial Ovarian Cancer

View Drugs

North Carolina

Drug(s) in Trial	Other Drug Names	Main Known Action
Atezolizumab	Tecentriq, Anti-PD-L1 Monoclonal Antibody MPDL3280A, MPDL3280A, RG7446	Blocks PD-L1 inhibition of T cells
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT03393884

I/II

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)

A Phase I/II Study Evaluating the Dosing, Safety, Efficacy, and Biological Activity of Intraperitoneal GEN-1 (IL-12 Plasmid Formulated With PEG-PEI-Cholesterol Lipopolymer) Administered in Combination With Neoadjuvant Chemotherapy (NACT) in Patients Newly Diagnosed With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

View Drugs

Alabama, California, Florida, Georgia, Massachusetts, Missouri, Montana, New Jersey, New York, North Carolina, Ohio, Oklahoma, Pennsylvania, Rhode Island, South Carolina, South Dakota, Tennessee, Wisconsin

Drug(s) in Trial	Other Drug Names	Main Known Action
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
GEN-1	PEG-PEI-cholesterol lipopolymer-encased IL-12 DNA plasmid vector GEN-1, EGEN-001, phIL-12-005/PPC	IL-12 receptor agonist
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

NCT02933073

Newly diagnosed stage III/IV ovarian cancer or platinum sensitive ovarian cancer at first recurrence

A Phase I Study of Oncoimmunome for the Treatment of Stage III/IV Ovarian Carcinoma

View Drugs

Connecticut

Drug(s) in Trial	Other Drug Names	Main Known Action
OncoImmunome		Anti-tumor immune response

NCT03054909

Stage III/IV ovarian cancer with stable disease or better after first-line IV/IP cisplatin and paclitaxel therapy (maintenance)

QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

View Drugs

Minnesota

Drug(s) in Trial	Other Drug Names	Main Known Action
ALT-803		Activates NK cells to stimulate immune response

NCT03607955

Newly diagnosed stage III/IV ovarian cancer (neo-adjuvant)

Phase IB Study of Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

View Drugs

Missouri, Oklahoma

Drug(s) in Trial	Other Drug Names	Main Known Action
AVB-S6-500		GAS6 antagonist
Carboplatin	Paraplatin, Novoplatinum	DNA damaging agent
Paclitaxel	Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXL	Microtubule stabilizer/mitotic inhibitor

If you have any questions or would like help with your search, please call us at: 858-264-5124 or email us at patientsupport@clearityfoundation.org.